Jazz Pharmaceuticals (NASDAQ: JAZZ) lists option-derived shares for sale via Merrill Lynch
Rhea-AI Filing Summary
Jazz Pharmaceuticals submitted a Form 144 indicating intended sales of common stock through Merrill Lynch with an associated date of 03/03/2026. The filing lists stock option-related lots dated 11/01/2021 (483 shares), 12/01/2021 (2,952 shares) and 01/03/2022 (2,565 shares).
Positive
- None.
Negative
- None.
Insights
Form 144 reports an intended sale of restricted/common shares via a broker.
The filing names Merrill Lynch as the broker and notes an associated date of 03/03/2026. The listed lots are tied to stock options with grant/exercise dates and explicit share counts: 11/01/2021 (483), 12/01/2021 (2,952) and 01/03/2022 (2,565).
Timing, exact proceeds treatment, and whether sales occurred in the past three months are not detailed in the excerpt; subsequent transaction reporting or brokerage confirmations would clarify execution and Rule 144 compliance.
Listed option lots quantify potential near-term share supply from an insider-related sale.
The excerpt shows three option-derived share amounts totaling 5, (follow the counts above) as discrete lots; each lot is labeled with its grant/exercise date and share count which market participants may watch as possible supply.
Actual market impact depends on whether and when those shares are sold; the excerpt does not state execution, pricing, or proceeds recipients.